• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[间变性甲状腺癌的最新进展——对外科医生有何重要意义?]

[Update on anaplastic thyroid cancer-What is relevant for surgeons?].

作者信息

Wächter Sabine, Bartsch Detlef K

机构信息

Klinik Klinik für Visceral‑, Thorax- und Gefäßchirurgie, Philipps-Universität Marburg, Baldingerstraße, 35043, Marburg, Deutschland.

出版信息

Chirurgie (Heidelb). 2025 Mar 25. doi: 10.1007/s00104-025-02277-0.

DOI:10.1007/s00104-025-02277-0
PMID:40131404
Abstract

Anaplastic thyroid cancer (ATC) is the rarest but also the most aggressive carcinoma entity of the thyroid gland. In recent years, treatment options have evolved and molecular oncological treatment approaches have gained in importance. The neoadjuvant use of these innovative therapies has the potential to convert previously unresectable tumors into a resectable state, thereby expanding surgical options and significantly improving the prognosis of patients. This article provides recommendations relevant for surgery for the diagnostics and treatment of ATC, based on a current literature review and the discussions of the S3 guideline conferences.

摘要

间变性甲状腺癌(ATC)是甲状腺最罕见但也是侵袭性最强的癌种。近年来,治疗方案不断发展,分子肿瘤学治疗方法愈发重要。这些创新疗法的新辅助应用有可能将先前无法切除的肿瘤转化为可切除状态,从而扩大手术选择范围并显著改善患者预后。本文基于当前文献综述以及S3指南会议的讨论结果,提供与ATC诊断和治疗手术相关的建议。

相似文献

1
[Update on anaplastic thyroid cancer-What is relevant for surgeons?].[间变性甲状腺癌的最新进展——对外科医生有何重要意义?]
Chirurgie (Heidelb). 2025 Mar 25. doi: 10.1007/s00104-025-02277-0.
2
The role of surgery in anaplastic thyroid cancer: A systematic review.手术在间变性甲状腺癌中的作用:一项系统综述。
Am J Otolaryngol. 2017 May-Jun;38(3):337-350. doi: 10.1016/j.amjoto.2017.02.005. Epub 2017 Mar 3.
3
[F]-FDG Uptake as a Marker of Residual Anaplastic and Poorly Differentiated Thyroid Carcinoma following -Targeted Therapy.[F]-氟代脱氧葡萄糖摄取作为靶向治疗后残余间变性和低分化甲状腺癌的标志物
AJNR Am J Neuroradiol. 2025 Jun 3;46(6):1260-1267. doi: 10.3174/ajnr.A8588.
4
Pregnancy among thyroid cancer survivors: do thyroidectomy and radioactive iodine matter?甲状腺癌幸存者的妊娠情况:甲状腺切除术和放射性碘治疗有影响吗?
Postgrad Med J. 2025 Jun 22;101(1197):636-643. doi: 10.1093/postmj/qgae197.
5
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
6
The use of Open Dialogue in Trauma Informed Care services for mental health consumers and their family networks: A scoping review.创伤知情护理服务中使用开放对话模式为心理健康消费者及其家庭网络提供服务:范围综述。
J Psychiatr Ment Health Nurs. 2024 Aug;31(4):681-698. doi: 10.1111/jpm.13023. Epub 2024 Jan 17.
7
What is the value of routinely testing full blood count, electrolytes and urea, and pulmonary function tests before elective surgery in patients with no apparent clinical indication and in subgroups of patients with common comorbidities: a systematic review of the clinical and cost-effective literature.在没有明显临床指征的患者和常见合并症患者亚组中,在择期手术前常规检测全血细胞计数、电解质和尿素以及肺功能测试的价值:对临床和成本效益文献的系统评价。
Health Technol Assess. 2012 Dec;16(50):i-xvi, 1-159. doi: 10.3310/hta16500.
8
Papillary thyroid carcinoma with exuberant nodular fasciitis-like stroma: treatment outcome and prognosis.伴有丰富结节性筋膜炎样间质的甲状腺乳头状癌:治疗结果与预后
J Laryngol Otol. 2006 Apr;120(4):338-42. doi: 10.1017/S0022215106000211.
9
[Update on follicular thyroid cancer-What is relevant for surgeons?].[滤泡性甲状腺癌的最新进展——对外科医生有何重要意义?]
Chirurgie (Heidelb). 2025 Mar 27. doi: 10.1007/s00104-025-02276-1.
10
Surgical outcomes of endoscopic thyroidectomy approaches for thyroid cancer: a systematic review and network meta-analysis.内镜甲状腺切除术治疗甲状腺癌的手术效果:系统评价和网络荟萃分析。
Front Endocrinol (Lausanne). 2023 Dec 4;14:1256209. doi: 10.3389/fendo.2023.1256209. eCollection 2023.

本文引用的文献

1
Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study.BRAF 靶向治疗后手术与 BRAF 突变型间变性甲状腺癌患者生存改善相关:单中心回顾性队列研究。
Thyroid. 2023 Apr;33(4):484-491. doi: 10.1089/thy.2022.0504. Epub 2023 Mar 20.
2
Mutation-based, short-term "neoadjuvant" treatment allows resectability in stage IVB and C anaplastic thyroid cancer.基于突变的短期“新辅助”治疗可使 IVB 和 C 期间变性甲状腺癌具有可切除性。
Eur Arch Otorhinolaryngol. 2023 Mar;280(3):1509-1518. doi: 10.1007/s00405-023-07827-y. Epub 2023 Jan 13.
3
Precision oncology for biliary tract tumors: it's written in blood!
胆管肿瘤的精准肿瘤学:这是用血写就的!
Ann Oncol. 2022 Dec;33(12):1209-1211. doi: 10.1016/j.annonc.2022.09.157. Epub 2022 Sep 28.
4
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.拉罗替尼治疗TRK融合阳性甲状腺癌患者的疗效与安全性。
Eur J Endocrinol. 2022 Apr 29;186(6):631-643. doi: 10.1530/EJE-21-1259.
5
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.2021 年美国甲状腺协会甲状腺间变性癌患者管理指南。
Thyroid. 2021 Mar;31(3):337-386. doi: 10.1089/thy.2020.0944.
6
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.仑伐替尼联合帕博利珠单抗是治疗间变性和低分化甲状腺癌的有效治疗选择。
Thyroid. 2021 Jul;31(7):1076-1085. doi: 10.1089/thy.2020.0322. Epub 2021 Apr 15.
7
Efficacy of Selpercatinib in -Altered Thyroid Cancers.塞尔帕替尼在改变的甲状腺癌中的疗效。
N Engl J Med. 2020 Aug 27;383(9):825-835. doi: 10.1056/NEJMoa2005651.
8
Anaplastic thyroid carcinoma: changing trends of treatment strategies and associated overall survival.间变性甲状腺癌:治疗策略的变化趋势及其与总体生存的关联。
Eur Arch Otorhinolaryngol. 2020 May;277(5):1507-1514. doi: 10.1007/s00405-020-05853-8. Epub 2020 Feb 14.
9
Lenvatinib vs. palliative therapy for stage IVC anaplastic thyroid cancer.乐伐替尼与晚期IVC间变性甲状腺癌姑息治疗的对比
Mol Clin Oncol. 2020 Feb;12(2):138-143. doi: 10.3892/mco.2019.1964. Epub 2019 Dec 13.
10
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.恩曲替尼治疗晚期或转移性 NTRK 融合阳性实体瘤患者的疗效:三项 I/II 期临床试验的整合分析。
Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11.